The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 22, 2022
Filed:
Sep. 21, 2018
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu, CN;
Lianyungang Runzhong Pharmaceutical Co., Ltd., Jiangsu, CN;
Centaurus Biopharma Co., Ltd., Beijing, CN;
Xiquan Zhang, Lianyungang, CN;
Wenwei Xu, Lianyungang, CN;
Mingming Li, Lianyungang, CN;
Minmin Kong, Lianyungang, CN;
Shufeng Wu, Lianyungang, CN;
Aiming Zhang, Lianyungang, CN;
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Lianyungang, CN;
LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., Lianyungang, CN;
CENTAURUS BIOPHARMA CO., LTD., Beijing, CN;
Abstract
The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)—N—((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2θ. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.